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INTRODUCTION
The recently updated US Preventive Services Task Force guide-
lines recommended against serum prostate-specific antigen 
(PSA)-based screening for prostate cancer on the grounds that 
the expected harms of screening (false-positive findings, over-
diagnosis, and overtreatment) outweigh the potential benefits.1 
Conceptually, overdiagnosis is defined as detection by screen-
ing of tumors that would not have presented clinically in a per-
son’s lifetime in the absence of screening.
The US Preventive Services Task Force recommendation 
was based primarily on evidence from the two largest mul-
ticenter randomized screening trials. The US Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial involved 
76,000 men aged 55 to 74 years who were randomized to 
either the screening arm and offered PSA test annually for 
6 years or the control arm and received usual care. After 
13 years of follow-up, the US Prostate, Lung, Colorectal, 
and Ovarian Cancer Screening Trial found no difference in 
prostate cancer-specific mortality between the two arms 
of the trial. However, more than 40% of men in the control 
arm underwent PSA testing. This study shows that there is 
no prostate cancer–related mortality benefit of organized 
annual screening compared with opportunistic screening.2 
By contrast, the European Randomized Study of Screening 
for Prostate Cancer involved 182,000 men aged 50 to 74 years 
randomized to the screening arm and offered PSA testing, on 
average, every 4 years, or to the control arm with no interven-
tion offered. The European Randomized Study of Screening 
for Prostate Cancer showed a 21% reduction in prostate can-
cer–related mortality after a median follow-up of 13 years. To 
prevent one death from prostate cancer, 781 men would need 
to be invited for screening and 27 additional cancers would 
need to be detected.3 These findings indicate that population 
screening for prostate cancer using PSA can prevent death 
from the cancer for a subset of men, but at a cost of overdiag-
nosis and subsequent overtreatment. This raises the question 
of whether targeted screening for prostate cancer can improve 
the benefit-to-harm ratio of screening.
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Purpose: This study aimed to quantify the probability of overdiag-
nosis of prostate cancer by polygenic risk.
Methods: We calculated the polygenic risk score based on 66 known 
prostate cancer susceptibility variants for 17,012 men aged 50–69 
years (9,404 men identified with prostate cancer and 7,608 with no 
cancer) derived from three UK-based ongoing studies. We derived 
the probabilities of overdiagnosis by quartiles of polygenic risk con-
sidering that the observed prevalence of screen-detected prostate 
cancer is a combination of underlying incidence, mean sojourn time 
(MST), test sensitivity, and overdiagnosis.
Results: Polygenic risk quartiles 1 to 4 comprised 9, 18, 25, and 48% 
of the cases, respectively. For a prostate-specific antigen test sensitiv-
ity of 80% and MST of 9 years, 43, 30, 25, and 19% of the prevalent 
screen-detected cancers in quartiles 1 to 4, respectively, were likely to 
be overdiagnosed cancers. Overdiagnosis decreased with increasing 
polygenic risk, with 56% decrease between the lowest and the highest 
polygenic risk quartiles.
Conclusion: Targeting screening to men at higher polygenic risk 
could reduce the problem of overdiagnosis and lead to a better bene-
fit-to-harm balance in screening for prostate cancer.
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Advances in genomics raise expectations of moving from the 
conventional “one-size-fits-all” to more personalized or risk-
stratified screening approach. By stratifying the population 
into several groups according to genetic risk alone or combined 
with other risk factors (such as age and family history), screen-
ing could be offered differentially to each population stratum 
with potentially improved benefit-to-harm ratio.4,5
To date, genome-wide association studies have identified 76 
prostate cancer susceptibility loci, to which ~30% of the famil-
ial risk of prostate cancer can be attributed.6 Assuming a log-
additive model of interaction between loci, these loci define a 
polygenic risk profile with a variance for the log relative risk 
distribution of 0.43 and estimated relative risks at the 5th and 
95th percentiles of 0.27 and 2.36, respectively.7 Such a distribu-
tion is limited in predicting prostate cancer for any given indi-
vidual because discrimination is limited (the area under the 
receiver operator characteristic curve is 0.68) (ref. 8); however, 
it could be used for risk stratification in prevention programs at 
the population level.6
A risk-stratified screening strategy for prostate cancer with 
eligibility for screening based on an absolute risk that is depen-
dent on age and polygenic risk profile has been shown to have 
the potential to improve the efficiency of the screening program 
by reducing the number of men invited to undergo screening 
while detecting most cancers potentially detectable by a con-
ventional age-based screening strategy.5 However, there is no 
evidence from empirical data that such personalized screening 
strategy would reduce harms of screening by reducing over-
diagnosis and subsequent overtreatment. Using mathemati-
cal modeling, this study aims at estimating the proportion of 
screen-detected cancers likely to be overdiagnosed by quartiles 
of polygenic risk profile.
MATERIALS AND METHODS
Study participants
We obtained genotyping and clinicopathological data for 17,012 
men aged 50 to 69 years (9,404 men identified with prostate 
cancer and 7,608 with no cancer) from three UK-based stud-
ies: Prostate Testing for Cancer and Treatment (ProtecT),9,10 
Studies of Epidemiology and Risk Factors in Cancer Heredity 
(SEARCH), and UK Genetic Prostate Cancer Study (UKGPCS)11 
(Supplementary Table S1 online). The ProtecT study provided 
prevalence screen data, and SEARCH and UKGPCS provided 
the clinical incidence data. Details of each of the studies have 
been published previously.
The ProtecT study is a UK-wide study of community-based 
PSA testing and randomized trial of subsequent prostate 
cancer treatment.9 PSA testing in the context of the ProtecT 
study is akin to prevalence screening. Between 2001 and 2008, 
~200,000 men between the ages of 50 and 69 years, ascertained 
through randomly selected general practices in nine regions in 
the United Kingdom, were invited for enrollment. Men who 
consented and met the eligibility criteria (82,429 men) were 
offered a PSA test. All men with PSA ≥3.0 ng/ml were offered 
transrectal ultrasound-guided biopsy using a 10-core lateral 
biopsy template. DNA extracts were available for 2,148 (74%) 
cases and for 6,648 men with no prostate cancer who provided 
consent for their blood samples to be used for genetic studies. 
Given that 2,895 men of 82,429 men were diagnosed with pros-
tate cancer as a result of PSA testing, then 2,148 cases would 
have been detected from a population of 61,160 PSA-tested 
men.
SEARCH is a population-based case–control study. Eligible 
cases are men younger than 70 years of age and registered 
with prostate cancer at the Eastern Cancer Registration and 
Information Centre (ECRIC) population-based cancer reg-
istry in East of England. Controls are men attending general 
practice who are frequency matched to cases by age and geo-
graphic region (http://ccge.medschl.cam.ac.uk/search-study/). 
Genotyping data were available for all SEARCH cases (n = 
4,099) and controls (n = 960) aged 50–69 years.
The UKGPCS11 includes men from families with multiple 
cases of prostate cancer, men diagnosed with prostate cancer 
at 60 years of age or younger throughout the United Kingdom, 
and systematic series from the prostate cancer clinic at the 
Royal Marsden NHS Foundation Trust. Genotyping data were 
available for 3,157 cases.
Prostate cancer was classified as localized disease with 
tumor-node-metastasis stage T2 and below and advanced dis-
ease (regional-distant) was classified as localized disease with 
tumor-node-metastasis stage T3 and above (low aggressive 
tumor, Gleason score <7; intermediate to highly aggressive 
tumor, Gleason score ≥7).
Genotyping and quality control
We obtained the genotyping data in two rounds. Genotyping 
outcome for 11,737 men on 70 known prostate cancer suscepti-
bility single-nucleotide polymorphisms (SNPs) were obtained 
from genotyping performed using a custom Illumina Infinium 
array (iCOGS), as described previously.7 ProtecT and SEARCH 
participants (N = 5,275) not genotyped using the iCOGS array 
were genotyped for 60 of these SNPs and for 10 highly cor-
related surrogate SNPs (r2 > 0.75) using Fluidigm BioMark 
96.96 Dynamic Array (Fluidigm, South San Francisco, CA) 
and TaqMan SNP assays (BioTrove, Woburn, MA) according 
to the manufacturer’s instructions.12 Both genotyping rounds 
were performed in the same laboratory. In each 384-well plate, 
2% duplicates and 1% PCR-negative controls (with no DNA) 
were included. Genotype intensity cluster plots were visually 
inspected, and the data were excluded if clustering was judged 
to be poor. We excluded individuals with more than 10% miss-
ing genotypes and excluded variants without genotype call 
(rs3850699, rs6062509, rs7210100), variants with a call rate less 
than 90% (rs675495), and variants that deviated from Hardy–
Weinberg equilibrium in controls at P < 0.005 (rs1465618). To 
harmonize the genotype calls in the two rounds of genotyp-
ing, when a variant was excluded, its surrogate marker was also 
excluded (rs339331 as surrogate SNP to rs675495).
Hence, the analysis was based on data from 66 loci associ-
ated with genome-wide significance level with susceptibility 
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for prostate cancer in European populations (Supplementary 
Table S2 online).
Polygenic risk score and absolute risk calculations
For individuals with missing genotype, we imputed the expected 
value based on the observed allele frequency. A polygenic risk 
score (PRS) for each individual was calculated as:
PRS = + +β β1 1 2 2x x xn n...β
where βn is the per-allele log odds ratio for variant n 
(Supplementary Table S2 online), and Xn represents the num-
ber of risk alleles carried by each individual at locus n (i.e., 0, 1, 
or 2). Thus, the risk conferred by each of the variants is assumed 
to be allele dose dependent with a multiplicative (log-additive) 
effect on a relative risk scale.13 Under the multiplicative model, 
the distribution of polygenic risk in the population at birth fol-
lows the normal distribution when relative risk is plotted on 
a logarithmic scale, with mean, μ, and variance σ2. We set the 
mean, μ = −σ2/2, so that the mean relative risk in the population 
at birth is equal to unity. The distribution of relative risk among 
cases at young ages is also log-normal with the same variance, 
but with a larger mean, μ + σ2 (ref. 13). Details are described in 
the Supplementary Data online.
We calculated the age-specific absolute risk for developing 
prostate cancer as:
λ λt t( ) = ( )0 exp( )PRS (1)
where λ0 t( )  is the baseline absolute risk in the population at 
age t, derived from the number of prostate cancer registrations, 
deaths from the cancer, deaths from all causes, and mid-year 
population estimates for England from 2002 to 2006, using 
DevCan 6.4.1 software (http://surveillance.cancer.gov/devcan/).
Derivation of estimates of probabilities of overdiagnosis
The observed prevalence of screen-detected prostate cancer is 
a combination of the underlying incidence, the duration of the 
preclinical detectable period (mean sojourn time (MST)), test 
sensitivity, and overdiagnosis.
The observed prevalence in polygenic risk stratum j is
P oIj j jz= +MSI ’ (2)
where M represents MST, S represents test sensitivity, and Ij 
represents the underlying age-conditional 1-year absolute risk 
for developing cancer in polygenic risk stratum j (all pertain-
ing to the nonoverdiagnosed cancers), I j’ represents the age-
conditional 1-year absolute risk among the clinically detected 
cases, and oI jz’  is the rate of overdiagnosis in stratum j. In this 
model, we posit that the logarithm of the rate of overdiagnosis 
is a linear function of the rate of clinically detected cases. In 
this model, o is the exponential of the constant term and z is 
the slope of the relationship in the logarithmic scale between 
incidence of clinical disease and overdiagnosed cancer.
We divided the polygenic risk distribution among the popu-
lation into quartiles. We calculated the observed prevalence of 
prostate cancer by risk quartiles within the ProtecT trial from 
the number of ProtecT cases and the extrapolated number 
of men tested in the ProtecT study within each risk quartile. 
We derived the incidence of clinically detected cancer by risk 
quartiles from SEARCH and UKGPCS after excluding cases 
recorded as screen detected. Assuming sojourn time and test 
sensitivity of nonoverdiagnosed cancers to be equal across the 
risk quartiles, we estimated the unknown parameters, o and z, 
from equation (2) across the four strata, such that:
P oIj j jz− =MSI ’ (2)
ln( ) ln( ) ln( ’ )P o z Ij j j− = +MSI × (3)
In a sensitivity analysis, we varied the sojourn time and the test 
sensitivity and derived estimates of the unknown parameters.
RESULTS
The distribution of the PRS based on 66 prostate cancer sus-
ceptibility variants had mean of −0.004 and variance of 0.40 
among men 50 to 69 years with no prostate cancer, and mean 
of 0.39 and variance of 0.40 among men with the cancer. The 
PRSs at the 25th, 50th, and 75th percentiles of the scaled risk 
distribution were −0.63, −0.20, and 0.23, respectively (Table 1). 
Polygenic risk quartiles 1 to 4 accounted for 9, 18, 25, and 48% 
of the cases, respectively (Table 2).
There was no statistically significant association between 
quartiles of PRS and stage (χ2 = 1.72; P = 0.63) or Gleason 
score categories (χ2 = 0.64; P = 0.93; Table 3). PSA level was 
available for 6,410 men with prostate cancer and for 6,646 men 
without prostate cancer. PSA level varied by polygenic risk, 
33% of men in polygenic risk quartile 1 compared with 66% 
of men in  quartile 4 had PSA ≥4 ng/ml (χ2 = 791.1; P < 0.001). 
After adjusting for stage and Gleason score, with every 1-point 
increase in PRS, the odds of having PSA ≥4 ng/ml compared 
with PSA < 4 ng/ml increased 1.23-fold (95% confidence 
interval: 1.10–1.37; P < 0.001).
Table 4 presents the observed prevalence of screen-detected 
cancer and incidence of clinically detected cancer by polygenic 
Table 1 Polygenic risk distribution among men 50–69 
years old with and without cancer in ProtecT, SEARCH, and 








Scaled mean −0.200 0.200
Variance 0.401 0.403
Interquartile range (based on the 
scaled distribution)
  25th percentile −0.627 −0.227
  50th percentile −0.200 0.200
  75th percentile 0.227 0.627
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risk quartile. Assuming MST for nonoverdiagnosed cancers of 
9 years14 and test sensitivity of 80%,14 the estimated o was 0.07 
and z was 0.37. A value of z of <1 indicates that the increase 
in incidence of clinical disease by risk score is greater than the 
increase in overdiagnosed disease. The rates of overdiagnosed 
cases estimated were 6, 8, 9, and 12 per 1,000 in quartiles 1–4, 
respectively. However, the prevalence of all cancers increased 
more rapidly with risk quartile at 15, 26, 36, and 63 per 1,000. 
Thus, although the absolute rate of overdiagnosis was esti-
mated to increase with polygenic risk, the proportion of screen-
detected cancers that are likely to be overdiagnosed decreased 
with an increase in polygenic risk quartiles. Therefore, 43, 30, 
25, and 19% of the cases were likely to be overdiagnosed in 
polygenic risk quartiles 1 to 4, respectively. The proportion of 
overdiagnosed cases was 56% lower in highest polygenic risk 
quartile compared with the lowest quartile.
Table 5 presents the proportion of the screen-detected can-
cers likely to be overdiagnosed by quartiles of polygenic risk in a 
sensitivity analysis using MST between 8 and 10 years and PSA 
test sensitivity between 80 and 90% and varying these param-
eters with risk quartiles, assuming shorter MST and higher test 
sensitivity with higher polygenic risk quartiles. The absolute 
value of the proportion of cancers overdiagnosed changed with 
changing these parameters; however, the pattern of lower pro-
portion of cancers likely overdiagnosed with increasing poly-
genic risk quartile remained.
DISCUSSION
To our knowledge, this is the first study to show that the pro-
portion of overdiagnosed cases in prostate cancer screening is 
likely to vary inversely by polygenic risk. The findings suggest 
that a polygenic risk-stratified screening strategy could reduce 
the problem of overdiagnosis.
Targeting screening to men at higher polygenic risk would 
reduce number of men likely to be overdiagnosed at a cost of 
detecting fewer men with cancer. Reducing the number of men 
invited to screening would further reduce harms associated 
with screening, such as false-positive findings and their diag-
nostic work-up. The optimal risk threshold will be population- 
and health care–specific. Preferences of men, organization of 
the screening program, the resource implications, economic 
evaluation, and assessment of the potential benefits and harms 
of a stratified screening program would all need to be explored 
to inform the optimal risk threshold.
It is likely that the trade-off between reducing overdiagnosed 
cancers and missing progressive cancers would further improve 
as more susceptibility loci are identified5 and as additional 
information is incorporated into the risk score, such as family 
history15,16 and baseline PSA level.17 Further studies are needed 
using empirical data to test the implications of adding infor-
mation regarding baseline PSA test level and family history to 
polygenic risk profiling for personalized screening in prostate 
cancer.
The individual and cumulative associations of the sus-
ceptibility loci with prostate cancer aggressiveness remain 





% of the 
controls
Extrapolated ProtecT 
population PSA tested No. of cases
% of the 
cases
No. of ProtecT PSA-
detected cases
No. of clinically 
detected casesa
N = 7,608 N = 61,160 N = 9,404 N = 2,148 N = 5,991
Q1 1,913 25.1 14,848 876 9.3 216 526
Q2 1,920 25.2 15,520 1,675 17.8 402 1,031
Q3 1,872 24.6 15,189 2,386 25.4 551 1,505
Q4 1,903 25.0 15,603 4,467 47.5 979 2,929
The observed prevalence of screen-detected cancers were based on ProtecT PSA-detected cases only, because the denominator populations for SEARCH and UKGPCS studies 
are not known.
ProtecT, Prostate Testing for Cancer and Treatment; PRS, polygenic risk score; PSA, prostate-specific antigen; SEARCH, Studies of Epidemiology and Risk Factors in Cancer 
Heredity; UKGPCS, UK Genetic Prostate Cancer Study.
 a398 cases from SEARCH and 867 cases from UKGPCS were recorded as screen detected and were excluded from the analysis.
Table 3 Association of stage, Gleason score, and PSA with 






(N = 6,425) %
Advanced 
stage  
(N = 1,934) % P value
0.632
Q1 584 9 189 10
Q2 1,130 18 354 18
Q3 1,613 25 484 25
Q4 3,098 48 907 47
Gleason score 
<7 (N = 3,958)
% Gleason score 
≥ 7 (N =3,738)
%
0.927
Q1 372 9 337 9
Q2 706 18 680 17
Q3 978 25 929 24
Q4 1,902 48 1,792 45
PSA < 4 ng/ml 
(N = 6,212)




Q1 1,472 24 714 10
Q2 1,579 25 1,225 18
Q3 1,531 25 1,722 25
Q4 1,630 26 3,183 47
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inconclusive.18,19 In our study, there was no association between 
PRS and stage or Gleason score. The absence of association 
between Gleason score and polygenic risk is consistent with 
our fundamental assumption of a common MST by PRS. The 
proportion likely overdiagnosed was found to be inversely 
associated with polygenic risk. It may be that genetic profile is 
associated with progression of disease independent of stage and 
Gleason score. Overdiagnosis depends not only on tumor biol-
ogy but also on the life expectancy of the individual. An aggres-
sive tumor still could be considered overdiagnosed if a person 
dies before the tumor presents symptomatically. To account for 
competing causes and age, we have used age-conditional abso-
lute risk for developing prostate cancer in deriving the expected 
prevalence by polygenic risk quartiles.
Our data on screen-detected cancers come from prevalence 
screening. Consequently, due to the absence of data regard-
ing interval cancers and incident screen-detected cancer, we 
could not derive the MST and PSA test sensitivity for differ-
ent polygenic risk strata using multi-state modeling. Previously, 
we derived the MST from prevalence data derived from the 
ProtecT study and the incidence data derived from English can-
cer registration among men 50 to 69 years, taking into account 
the sensitivity of the PSA test estimated from external data.14 
We have estimated PSA test sensitivity as 80% and MST as 
11 years.14 Our estimate of PSA test sensitivity is comparable 
to the estimate of 85% determined by Hakama et al.20 using 
the incidence method based on randomized prostate cancer 
screening trial in Finland. The incidence method is free from 
overdiagnosis bias.20 As such, this estimate is appropriate to 
use to derive the prevalence of progressive cancers. Our esti-
mate of MST is comparable to the estimates from the European 
Randomized Study of Screening for Prostate Cancer. In the 
European Randomized Study of Screening for Prostate Cancer, 
the mean lead time ranges between 4 and 8 years.21 The mean 
lead time is approximately half the duration of the sojourn time 
for prevalence screening.22 Our estimate of the MST is based on 
prevalent cases, which include both progressive and overdiag-
nosed cancers. As such, it is expected that the sojourn time of 
progressive disease will be shorter than 11 years.
It is not known if the test sensitivity and tumor behav-
ior vary by genetic risk. It may be that the test sensitivity 
is higher in detecting cancers with higher genetic risk and 
these cancers have shorter sojourn time. In a sensitivity 
analysis, we have used values for MST for progressive cancer 
between 8 and 10 years and for PSA test sensitivity between 
80 and 90%. Previously using the same prevalent screen 
data, ProtecT data, we have estimated that approximately 
one-quarter of the screen-detected cases among men aged 

















clinical cases I j
′
Q1 0.015 0.0013 0.80 9 0.0094 0.0018
Q2 0.026 0.0024 0.80 9 0.0170 0.0030
Q3 0.036 0.0035 0.80 9 0.0252 0.0046
Q4 0.063 0.0073 0.80 9 0.0525 0.0102
PRS, polygenic risk score; PSA, prostate-specific antigen.
Table 5 Sensitivity analysis with varying mean sojourn time (MST) and PSA test sensitivity (S) and the proportion of cases 
likely overdiagnosed, by quartile of polygenic risk
Percentage of the cancers detected likely to 
be overdiagnosed (%)
o z Q1 Q2 Q3 Q4
Weighted 
averagea
MST and test sensitivity constant across the quartiles of polygenic risk
MST = 8 years; S = 80% 0.20 0.53 50 37 33 29 33
MST = 9 years; S = 80% 0.07 0.37 43 30 25 19 25
MST =10 years; S = 80% 0.01 0.01 39 22 16 9 16
MST = 8 years; S = 85% 0.13 0.46 46 33 29 24 29
MST = 9 years; S = 85% 0.02 0.22 40 25 20 14 20
MST = 10 years; S = 85% 0.00 -0.90 45 16 8 2 10
MST and test sensitivity varied across the quartiles
Q1–Q2: MST = 9 years; S = 80% 0.07 0.37 43 30 25 19 25
Q3–Q4: MST = 8 years; S = 90%
Q1–Q2: MST = 10 years; S = 80% 0.35 0.68 33 27 25 25 26
Q3–Q4: MST = 8 years; S = 85%
PSA, prostate-specific antigen.
aWeighted average is calculated based on weights as the proportion of cases occurring within each quartile—9, 18, 25, and 48% for Q1–Q4, respectively.
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50–69 years would be overdiagnosed.14 Our weighted aver-
age estimates of probabilities of overdiagnosis across the risk 
strata gave comparable figures when taking sojourn time of 
9 years with 80% test sensitivity or varying sojourn time and 
test sensitivity across risk strata as 8 and 10 years and 80 and 
90% for polygenic risk quartiles 1 and 2 and quartiles 3 and 
4, respectively.
Evidence from randomized screening trial on probabili-
ties of overdiagnosis, natural history of the disease, screen-
ing test performance, and cancer-specific mortality stratified 
by risk is warranted.  This is to estimate the absolute benefits 
and harms of screening by polygenic risk threshold. Further 
research is needed to explore whether genetic testing for 
stratification and eligibility for screening would be accept-
able to health professionals and to the public, and how the 
public will perceive not offering or less frequent offering 
of screening to subgroups of the population at low risk for 
cancer.23
In summary, tailoring of screening strategies to different risk 
groups may improve the balance between benefits and harms 
of screening. Targeting screening to men at higher polygenic 
risk could potentially reduce the problem of overdiagnosis in 
prostate cancer.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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